Many of these clients are validated oncogenic drivers of lung adenocarcinoma including mutant EGFR [38], mutant BRAF [39], wild-type and mutant HER2 [40,41], and the EML4-ALK translocation product [42]. Here, EGFR is linked to lung adenocarcinoma.